J Korean Diabetes.  2023 Mar;24(1):18-23. 10.4093/jkd.2023.24.1.18.

Diabetes and Sexual Dysfunction

• Kim JD

• KMID: 2540916
• DOI: http://doi.org/10.4093/jkd.2023.24.1.18

Abstract

Type 2 diabetes can produce various sexual dysfunctions in both men and women. Prevalence of sexual dysfunction is 25~75% in type 2 diabetes, which is three times that of the general population. As hyperglycemia persists, atherosclerosis progresses, and macrovascular and microvascular complications can occur. Autonomic neuropathy and hypogonadism are principal causes of various sexual dysfunctions such as erectile dysfunction, retrograde ejaculation, and premature ejaculation in males and loss of libido, vaginal dryness, anorgasmia, and dyspareunia in females. Although erectile dysfunction is reversible in early stages, it is more difficult to control as diabetes and associated autonomic dysfunction and microvascular complications progress. Sexual dysfunction can decrease quality of life in type 2 diabetes patients and is a marker of vascular dysfunction. Sexual dysfunction has prognostic value for cardiovascular events in type 2 diabetes. This illustrates the importance of sexual function evaluation in type 2 diabetes patients.

Keyword

Diabetes complications; Erectile dysfunction; Hypogonadism

Reference

1.Korean Diabetes Association. Diabetes. 5th ed.Seoul: Panmun Education;2018. p. 663–74.

2.Gandhi J., Dagur G., Warren K., Smith NL., Sheynkin YR., Zumbo A, et al. The role of diabetes mellitus in sexual and reproductive health: an overview of pathogenesis, evaluation, and management. Curr Diabetes Rev. 2017. 13:573–81.

3.Park KJ., Paick JS. Diabetic erectile dysfunction. Korean J Androl. 2009. 27:135–52.

4.Yoon HN., Park KS. Pharmacologic management of female sexual dysfunction. J Korean Med Assoc. 2016. 59:136–43.

5.Moon DG. The risk factors, diagnosis and treatment guideline of erectile dysfunction. J Korean Med Assoc. 2015. 58:443–51.

6.Kamenov ZA. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes. 2015. 123:141–58.

7.Cho NH., Ahn CW., Park JY., Ahn TY., Lee HW., Park TS, et al. Prevalence of erectile dysfunction in Korean men with type 2 diabetes mellitus. Diabet Med. 2006. 23:198–203.

8.Defeudis G., Mazzilli R., Tenuta M., Rossini G., Zamponi V., Olana S, et al. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022. 38:e3494.

9.Chung WS. Pharmacological management of male sexual dysfunction. J Korean Med Assoc. 2008. 51:770–8.

10.Anderson SG., Hutchings DC., Woodward M., Rahimi K., Rutter MK., Kirby M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016. 102:1750–6.

11.Hackett G., Jones PW., Strange RC., Ramachandran S. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes. 2017. 8:104–11.

12.Corona G., Giagulli VA., Maseroli E., Vignozzi L., Aversa A., Zitzmann M, et al. THERAPY OF ENDOCRINE DIS-EASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016. 174:R99–116.

13.Kumar S., Khatri M., Memon RA., Velastegui JL., Podaneva KZ., Gutierrez DB, et al. Effects of testosterone therapy in adult males with hypogonadism and T2DM: a me-ta-analysis and systematic review. Diabetes Metab Syndr. 2022. 16:102588.

14.Hackett G., Cole N., Bhartia M., Kennedy D., Raju J., Wilkin-son P; BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014. 11:840–56.